<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931563</url>
  </required_header>
  <id_info>
    <org_study_id>D3468C00003</org_study_id>
    <nct_id>NCT04931563</nct_id>
  </id_info>
  <brief_title>Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Anifrolumab in Asian Participants With Active Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of an intravenous treatment&#xD;
      regimen of anifrolumab versus placebo in Asian participants with active systemic lupus&#xD;
      erythematosus (SLE).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III, multicenter, multinational, randomised, double-blind, placebo-controlled&#xD;
      study to evaluate the efficacy and safety of an intravenous treatment regimen of 300 mg&#xD;
      anifrolumab versus placebo in participants with moderate to severe, autoantibody positive SLE&#xD;
      while receiving SOC treatment. The study will be performed in participants aged 18 to 70&#xD;
      years of age.&#xD;
&#xD;
      Participants with a confirmed diagnosis of moderate to severe active SLE and are currently&#xD;
      receiving SOC comprising of oral corticosteroids (OCSs) and/or antimalarial, and/or&#xD;
      immunosuppressants, either alone or any combination of them, for a required duration of&#xD;
      treatment at a stable dose, as described in the inclusion criteria shall be included.&#xD;
      Participants must have eligible scores for SLEDAI-2K, BILAG-2004, and PGA as confirmed by the&#xD;
      DACRT.&#xD;
&#xD;
      Eligible participants will be randomised in a 1:1 ratio to receive either a fixed intravenous&#xD;
      dose of 300 mg anifrolumab plus SOC or placebo plus SOC every 4 weeks (Q4W) for a total of 13&#xD;
      doses (Week 0 to Week 48), with the primary endpoint evaluated at the Week 52 visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 13, 2021</start_date>
  <completion_date type="Anticipated">June 13, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of participants achieving BICLA response</measure>
    <time_frame>Week 52</time_frame>
    <description>Composite endpoint (BICLA), defined by meeting all of the following criteria:&#xD;
Reduction of all baseline BILAG-2004 A to B/C/D and baseline BILAG-2004 B to C/D, and no BILAG-2004 worsening in other organ systems, where worsening is defined as ≥1 new BILAG-2004 A or ≥2 new BILAG-2004 B&#xD;
No worsening from baseline in SLEDAI-2K, where worsening is defined as an increase from baseline of &gt;0 points in SLEDAI-2K&#xD;
No worsening from baseline in participants' lupus disease activity, where worsening is defined as an increase of ≥0.30 points on a 3-point PGA visual analogue scale (VAS)&#xD;
No discontinuation of investigational product&#xD;
No use of restricted medications beyond the protocol allowed threshold a before assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants who achieve an oral corticosteroid (OCS) dose ≤7.5 mg/day at Week 40, which is maintained through Week 52 in the subgroup of those with baseline OCS ≥10 mg/day</measure>
    <time_frame>Week 52</time_frame>
    <description>Maintained OCS reduction defined by meeting all of the following criteria:&#xD;
Achieve an OCS dose of ≤7.5 mg/day prednisone or equivalent by Week 40&#xD;
Maintain an OCS dose ≤7.5 mg/day prednisone or equivalent from Week 40 to Week 52&#xD;
No discontinuation of investigational product&#xD;
No use of restricted medications beyond the protocol allowed threshold a before assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with a ≥50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score at Week 12 in the sub-group of those with baseline CLASI activity score ≥10</measure>
    <time_frame>Week 12</time_frame>
    <description>50% reduction in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) activity score compared to baseline defined by meeting all of the following criteria:&#xD;
Achieve ≥50% reduction of CLASI activity score at Week 12 compared to baseline&#xD;
No discontinuation of investigational product&#xD;
No use of restricted medications beyond the protocol allowed threshold a before assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized flare rate</measure>
    <time_frame>Week 52</time_frame>
    <description>Annualised flare rate with flare defined as either 1 or more new BILAG-2004 A or 2 or more new BILAG-2004 B items compared to the previous visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">328</enrollment>
  <condition>Active Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>300 mg placebo will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48 for a total of 13 doses. Each dose must be at least 14 days apart.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anifrolumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>300 mg anifrolumab will be administered via controlled IV infusion pump into a peripheral vein over a minimum of 30 minutes Q4W from Week 0 to Week 48 for a total of 13 doses. Each dose must be at least 14 days apart.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Anifrolumab</intervention_name>
    <description>Intravenous infusion (IV)</description>
    <arm_group_label>anifrolumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Intravenous infusion (IV)</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:&#xD;
&#xD;
          1. Aged 18 to 70 years.&#xD;
&#xD;
          2. Body weight ≥ 40 kg.&#xD;
&#xD;
          3. Confirmed diagnosis of SLE(1997 ACR revised criteria) for ≥ 24 weeks.&#xD;
&#xD;
          4. Must be receiving at least one of the following SOC regimens at screening:&#xD;
&#xD;
               1. oral prednisone monotherapy: ≥ 7.5 mg/day and ≤ 40 mg/day, stable for &gt; 2 weeks;&#xD;
&#xD;
               2. Immunosuppressant(s) with or without OCS: antimalarials, AZA, MMF, MTX,&#xD;
                  mizoribine permitted; stable for ≥ 8 weeks; maximum dose required;&#xD;
&#xD;
               3. Oral prednisone plus immunosuppressant: start date, stability and maximum dose&#xD;
                  required.&#xD;
&#xD;
          5. At least one of these antibodies positive: ANA, anti-dsDNA and anti-Smith.&#xD;
&#xD;
          6. At screening, SLEDAI-2K score ≥ 6 points and &quot;Clinical&quot; SLEDAI-2K score ≥4 points, and&#xD;
             BILAG with at least 1 level A organ system or 2 level B organ system, and PGA score ≥&#xD;
             1.0.&#xD;
&#xD;
          7. Chest imaging shows no clinically significant abnormalities (unless due to SLE).&#xD;
&#xD;
          8. No evidence or medical history of active TB, indeterminate TB should be referred to a&#xD;
             TB specialist.&#xD;
&#xD;
          9. All participants should use effective contraception methods as protocol requests.&#xD;
&#xD;
         10. Negative SARS-CoV-2 RT-PCR test result at screening and no known or suspected COVID-19&#xD;
             infection or exposure.&#xD;
&#xD;
        Key exclusion criteria:&#xD;
&#xD;
          1. History or current diagnose of clinically significant non-SLE related vasculitis,&#xD;
             severe or unstable neuropsychiatric SLE, active severe SLE-driven renal disease,&#xD;
             catastrophic anti-phospholipid syndrome, inflammatory joint or skin disease other than&#xD;
             SLE, non-SLE disease that has required treatment of certain dosage of corticosteroid.&#xD;
&#xD;
          2. History or evidence of suicidal ideation or suicidal behavior.&#xD;
&#xD;
          3. History or current diagnose of MTCD or overlap syndrome, unless overlap with RA or&#xD;
             MTCD which has developed into SLE.&#xD;
&#xD;
          4. History of recurrent infection requiring hospitalization and IV antibiotics, or&#xD;
             opportunistic infection requiring hospitalization or IV antimicrobial treatment within&#xD;
             3 years of randomization, or clinically significant chronic infection within 3 months,&#xD;
             or recent infection still under treatment.&#xD;
&#xD;
          5. History of immunodeficient condition, HIV positive included.&#xD;
&#xD;
          6. Confirmed HBsAg positive, or HBcAb positive and HBV DNA detectable, or hepatitis C&#xD;
             antibody positive.&#xD;
&#xD;
          7. History of severe case of herpes zoster.&#xD;
&#xD;
          8. Herpes zoster, CMV or EB infection which has not completely resolved within 12 weeks&#xD;
             before screening.&#xD;
&#xD;
          9. Acute COVID-19 infection or history of severe COVID-19.&#xD;
&#xD;
         10. History of cancer, apart from cured squamous or basal cell carcinoma and cervical&#xD;
             cancer in situ.&#xD;
&#xD;
         11. Women participants with abnormal pap smear results.&#xD;
&#xD;
         12. Prior receipt of anifrolumab ,or any commercially available biologic agent, or protein&#xD;
             kinase inhibitor or any investigational product within 5 half-lives, including B&#xD;
             cell-depleting therapy, belimumab, JAK or BTK inhibitor.&#xD;
&#xD;
         13. Known history of allergy to any component of the IP formulation or protein related&#xD;
             products.&#xD;
&#xD;
         14. Receipt of any of the following:&#xD;
&#xD;
               1. Intramuscular or IV glucocorticosteroids within 6 weeks;&#xD;
&#xD;
               2. Any live or attenuated vaccine within 8 weeks;&#xD;
&#xD;
               3. Any restricted medication listed in protocol;&#xD;
&#xD;
               4. Blood transfusion within 4 weeks. 15 Regular use of &gt; 1 NSAID within 2 weeks or&#xD;
                  receipt of fluctuating doses of a NSAID within 2 weeks.&#xD;
&#xD;
        16. Certain laboratory test results requirements. 17. Concurrent enrolment in another&#xD;
        clinical study. 18. History or current alcohol, drug or chemical abuse within 1 year. 19.&#xD;
        Major surgery within 8 weeks or planned elective major surgery.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baoding</city>
        <zip>071000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changzhi</city>
        <zip>46000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>ChongQing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chuangchun</city>
        <zip>130012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <zip>10050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jining</city>
        <zip>272011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kunming</city>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Luoyang</city>
        <zip>471003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shengyang</city>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <zip>110001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenzhen</city>
        <zip>518020</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suzhou</city>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urumqi</city>
        <zip>831118</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xi'an</city>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Xiamen</city>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhengzhou</city>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shatin</city>
        <zip>00000</zip>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gwangju</city>
        <zip>501-757</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jung-gu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04763</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>143-729</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>6591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwon-si</city>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao City</city>
        <zip>PH-8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Davao</city>
        <zip>8000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iloilo City</city>
        <zip>5000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lipa City</city>
        <zip>4217</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Manila</city>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1112</zip>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>81362</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung City</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tainan</city>
        <zip>70403</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei City</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tao-Yuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hat Yai</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Muang</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>June 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

